oncoletter · Cabozantinib TKI targeting VEGF receptors, MET, AXL, RET Improves PFS in advanced...
17
oncoletter · Cabozantinib TKI targeting VEGF receptors, MET, AXL, RET Improves PFS in advanced renal cell carcinoma in 1st line (vs. sunitinib)l and in 2nd line (vs. everolimus)